Figure 6.

Akt inhibition enhances the antitumor activity of 4EGI-1 in vivo. Four groups of mice with MCF7 xenografts were treated with vehicle control, 4EGI-1 (50 mg/kg/day, intra-peritoneal injection) or MK2206 (100 mg/kg/two days, oral gavage) individually or in combination. Tumor growth (A) and body weights of mice (C) were monitored over a 20-day period. (B) Tumor weight after necropsy. Data are presented as means ± s.d. *P < 0.05, compared to the vehicle control. ^#P < 0.05, compared to the 4EGI-1 treatment. (D) Tumor samples were analyzed by protein gel blot with indicated antibodies.